Malignant Mesothelioma — Trials

Malignant Mesothelioma — Trials · CancerIndex

Clinical trials

Registered studies

478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 96
Recruiting: 55
Ph III recruiting: 1
Growth YoY: —
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.4%
Trials / 1,000 deaths: 45.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (81)

clinicaltrialsPublishedShowing 101–109 of 109 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00137826	Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma	completed	Phase 2	37	Dana-Farber Cancer InstituteOTHER	1	Dec 26, 2011	clinicaltrials
NCT00407459	Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma	completed	Phase 2	77	Armando Santoro, MDOTHER	1	Sep 2, 2011	clinicaltrials